Utility of immunohistochemistry in breast cancer practice

Breast Cancer

Volumn 11, Issue 4, 2004, Pages 334-338

  Umemura, Shinobu ^a   Osamura, R Yoshiyuki ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

Breast cancer; HER2; Hormone receptors; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BREAST TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; NEOPLASM; PREDICTION AND FORECASTING; REVIEW; STANDARD;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, HORMONE-DEPENDENT; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2;

EID: 21644446298     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02968039     Document Type: Review

References (43)

1. Coons AH, Creech HJ, Jones RN, et al: The demonstration of pneumococcal antigen in tissues by the use of fluorescent antibody. J Immunol 45:159, 1942.
2. Nakane PK: Simultaneous localization of multiple tissue antigens using the peroxidase-labeled antibody method: a tudy on pituitary glands of rat. J Histochem Cytochem 16:557-560, 1968.
3. Mason TE, Phifer RF, Spicer SS, et al: An immunoglobulin-enzyme bridge method for localizing tissue antigens. J Histochem Cytochem 17:563-569, 1969.
4. Sternberger LA, Hardy PH, Cuculis JJ, et al: The unlabled antibody anzyme method of immunocytochemisty. Preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem 18:315-333, 1970.
5. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580, 1981. (Pubitemid 11147380)
6. Hockenbery D, Nunez G, Milliman C, et al: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-3346, 1990.
7. Nagashima T, De Armond SJ, Murovic J, et al: Immunocytochemical demonstration of S-phase cells by anti-bromodeoxyuridine monoclonal antibody in human brain tumor tissues. Acta Neuropathol 67:155-159, 1985. (Pubitemid 15021223)
8. Mukai M, Torikata C, Iri H, et al: Immunohistochemical identification of aggregated actin filaments in formalin-fixed, paraffin-embedded sections. I. A study of infantile digital fibromatosis by a new pretreatment. Am J Surg Pathol 16:110-115, 1992.
9. Pearlman WH, Gueriguian JD, Sawyer ME: A specific progesterone-binding component of human breast cyst fluid. J Biol Chem 248:5736-5741, 1973.
10. Shi R P C, Iwasiow BM: Prolactin-inducible proteins in human breast cancer cells. J Biol Chem 260:11307-11313, 1985. (Pubitemid 16253298)
11. Wick MR, Lillemore TJ, Copland GT, et al: Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol 20:281-287.
12. Satoh F, Umemura S, Osamura RY: Immunohistochemical analysis of GCDFP-15 and GCDFP-24 in mammay and non-mammary tissue. Breast Cancer 7:49-55, 2000.
13. Leong AS-Y, Cooper K, Leong F J W-M: Gross cystic disease fluid protein-15 (GCDFP-15, BRST-2). In: Leong AS-Y, Cooper K, Leong FJW-M eds, Manual of Diagnostic Antibodies for Immunohistology, 2nd ed, Greenwich Medical Media Ltd., London, ppml-243, 2003.
14. Wang NP, Bacchi CE, Gown AM: Coordinate expression of cytokeratins 7 and 20 define unique subsets of carcinomas. Appl Immunohistochem 3:99407, 1995.
15. Moll R, Franke WW, Schiller DL, et al: The catalog of human cytokeratins: patterns of expression in normal epithelial, tumors and cultured cells. Cell 31:11-24, 1982. (Pubitemid 13215192)
16. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a few method of treatment with illustrative cases. Lancet 2:104-107, 1896.
17. Koenders A, Thorpe SM: Standardization of steroid receptor assays in human breast cancer, I: reproducibility of estradiol and progesterone receptor assays. Eur J Cancer Clin Oncol 19:1221-1229, 1983. (Pubitemid 13048518)
18. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351:1451-1467, 1998.
19. Umemura S, Itoh H, Ohta M, et al: Immunohistochemical evaluation of hormone receptor for routine practice of breast cancer: highly sensitive procedures significantly contribute to the correlation with biochemical assays. Appl Immunohistochem Mol Morphol 11:62-72, 2003. (Pubitemid 36373007)
20. Remmele W, Stegner H: Immunohistochemischer nachweis von ostrogenrezeptoren (ER-ICA) im mammakarzinomgewebe: Worschlag zur einheitlichen formulierung des untersuchungsbefundes. Dtsch Arztebl 83:3362-3364, 1986.
21. Reiner A, Reiner G, Spona J, et al: Histopathologic characterization of human breast cancer in correlation with estrogen receptor status. A comparison of immunocytochemical and biochemical analysis. Cancer 61:1149-1154, 1988. (Pubitemid 18078604)
22. Leake R, Barnes D, Pinder S, et al: Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. J Clin Pathol 53:634-635, 2000. (Pubitemid 30640178)
23. Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathol 11:155-168, 1998. (Pubitemid 28144151)
24. Umemura S, Itoh J, Itoh H, et al: Immunohistochemical evaluation of hormone receptors in breast cancer; Determining which evaluation system is suitable for highly sensitive procedures. Appl Immunohistochem Mol Morphol, 2003 (in press).
25. Harvey JM, Clark GM, Osborne, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999. (Pubitemid 29220854)
26. Schubert D, Heinemann S, Carlisle W, et al: Clonal cell lines from the rat central nervous system. Nature 249:224-227, 1974.
27. Shih C, Padhy LC, Murray M, et al: Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290:261-264, 1981. (Pubitemid 11149660)
28. Schechter AL, Hung MC, Vaidyanathan L, et al: The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229:976-978, 1985. (Pubitemid 16248489)
29. Pinkas-Kramarski R, Soussan L, Waterman H, et al: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBOJ 15:2452-2467, 1996. (Pubitemid 26151185)
30. Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165-184, 1994.
31. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001. (Pubitemid 33674041)
32. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987. (Pubitemid 17231334)
33. Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998. (Pubitemid 28439960)
34. Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135, 1995.
35. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049-1056, 1992.
36. Ogura H, Akiyama F, Kasumi F, et al: Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry. Breast Cancer 10:234-240, 2003.
37. Perez EA, Roche PC, Jenkins RB, et al: HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77:148-154, 2002. (Pubitemid 34118890)
38. Press MF, Slamon DJ, Flom KJ, et al: Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20:3095-3105, 2002. (Pubitemid 34791099)
39. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001. (Pubitemid 32222155)
40. Rhodes A, Jasani B, Anderson E, et al: Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processess cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 118:408-417, 2002. (Pubitemid 37046339)
41. Cell Markers and Cytogenetics Committees, College of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 126:803-808, 2002.
42. Paik S, Bryant J, Tan-Chiu E, et al: Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852-854, 2002. (Pubitemid 34705057)
43. Paik S, Tan-Chiu E, Bryant J, et al: Allegheny General Hospital, Pittsburgh, PA; Cancer Research Network, Plantation, FL. Successful quality assurance program for HER2 testing in the NSABP trial for Herceptin. Breast Cancer Res Treat 76(Suppl 1), Abstract 9, 2002.